DYRK1A is one of five members of the Dual-specificity tyrosine (Y) phosphorylation-Regulated Kinase (DYRK) family. The DYRK1A gene is located in the Down syndrome critical region and regulates cellular processes related to proliferation and differentiation of neuronal progenitor cells during early development. This has focused research on to its role in neuronal degenerative diseases, including Alzheimer's and Down syndrome; recent studies have also shown a possible role of DYRK1A in diabetes. Here we report a variety of scaffolds not generally known for DYRK1A inhibition, demonstrating their effects in in vitro assays and also in cell cultures. These inhibitors effectively block the tau phosphorylation that is a hallmark of Alzheimer's Disease.
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INTRODUCTION
Alzheimer's disease (AD) is the primary cause of dementia in the elderly 1 . AD affects less than 5% of individuals 65 years of age and younger, but the incidence of AD reaches nearly 40% in patients 85 years of age and older 1 . This neurodegenerative disorder is characterized by neuronal death and loss of gray matter in the frontal cortex and hippocampus. This neurodegenerative disorder is characterized by neuronal death and loss of gray matter in the frontal cortex and hippocampus. Memory loss is a typical symptom of AD and has been linked to the accumulation of amyloid plaques and neurofibrillary tangles (NFTs) 2 . The latter process is mediated by hyperphosphorylation of tau proteins that are inactive and form multiple aggregates. According to the β−amyloid cascade hypothesis, the deposition of insoluble β-amyloid is responsible for neuronal death. Plaques are constituted by β-amyloid peptides (Aβ) that are generated via the cleavage of the amyloid precursor protein (APP) by β-and γ-secretases. Aβ-fragments, 37-42 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60   3 amino acids in length, may produce soluble oligomers, although they aggregate into insoluble β-amyloid plaques in AD 2, 3 . Alternatively, the insoluble hyperphosphorylated tau proteins and the buildup of NFTs may be the etiology of neuronal death [4] [5] [6] . Both mechanisms of neuronal pathology depend on the kinase DYRK1A, which regulates the cell cycle, neuronal differentiation and synaptic transmission 7 .
Increased levels of DYRK1A are present in the brain of patients with AD and in other neurodegenerative diseases, including Parkinson, Huntington and Pick syndromes 7 . The human DYRK1A gene is located in the Down syndrome critical region (DSCR) encoded by chromosome 21 , and the overexpression of DYRK1A likely contributes to the neurological abnormalities of this disorder 8 .
DYRK1A increases the secretase-mediated cleavage of APP into Aβ peptides. DYRK1A
phosphorylates APP directly 9 and the Aβ peptides stimulate DYRK1A expression in a positive feedback loop 9 . Additionally DYRK1A phosphorylates presenilin 1 (PSEN1) 10 , one of the four core proteins in the γ-secretase complex, which enhances secretase activity. DYRK1A
phosphorylates human microtubule associated protein tau at eleven different sites 11 , whereby most of the tau protein becomes hyperphosphorylated. The initial phosphorylation of tau by DYRK1A triggers tau phosphorylation by GSK3β, which potentiates self-aggregation and fibril formation in vitro 11, 12 . Because of the central role of DYRK1A in the development and progression of AD, DYRK1A has emerged as a high priority target for inhibition, offering a novel approach for the treatment of AD. In recent years, evidence has built up that point to a role of DYRK1A in diabetes and β-cell proliferation [13] [14] [15] , expanding the pharmaceutical application of a DYRK1A inhibitor. Therefore, we screened a diverse set of scaffolds for their ability to inhibit DYRK1A kinase activity and to prevent tau phosphorylation. The diversity of the novel scaffolds 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 4 and the binding modes determined by crystal structure and in vitro assays may lead to the development of novel strategies for the clinical treatment of AD.
RESULTS

Identification of novel DYRK1A inhibitors
Novel DYRK1A inhibitors were identified by employing KinomeScan TM screening data of an in-house library of approximately 1,000 compounds including previously synthesized kinase inhibitors. 23 compounds were chosen as candidates for activity assay and their ability to inhibit the phosphorylation of DYRKtide (RRRFRPASPLRGPPK) by DYRK1A at a fixed concentration of 20 µM with an ATP regenerative assay (Cook et al. 16 ). The results for the most promising compounds are shown in Table 1 and all the 23 compounds are shown in the supporting information Table S1 . The inhibitors had a broad range of activity: 8 compounds showed strong inhibition (remaining activity <5%), 8 compounds showed moderate inhibition (11%-46% remaining activity) and 6 compounds showed little or no inhibition (70%-100% remaining activity). 15 inhibitors that showed at least 50% inhibition were titrated in decreasing concentrations (200µM-20nM) to determine the IC 50 and K i values.
Compounds AC12, AC13, AC14, AC15 and AC27 were found to possess highest ability to inhibit the phosphorylation of DYRKtide, with K i values around 100-250 nM. AC7, AC24 and AC25 inhibitors showed K i values of around 326 nM -570 nM. Inhibitors with identical core scaffolds revealed similar K i values, as seen for the two pairs AC12 and AC15 (~104 nM and ~158 nM), and AC24 and AC25 (383 nM and 575 nM, respectively). The remaining compounds (AC2, AC8, AC16, AC18, AC20, AC22, and AC23) were weaker compared to the 8 inhibitors 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 discussed above and exhibited K i values ranging from 1.7 µM to >8 µM (supporting information   Table S1 ). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 6 Figure 1 . Structures of the nine novel DYRK1A inhibitors, representing six different core scaffolds. AC12 and AC15 share one core structure, and AC24, AC25 and AC28 share a second type of the core structure.
Tau phosphorylation inhibitory activity assay in cells
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Eight compounds that displayed inhibitory activity in vitro (see Table 1 ) were further tested in a cell line to establish whether they possessed the capacity to inhibit tau phosphorylation by DYRK1A. Expression vectors encoding FLAG-tagged TAU and EGFP-tagged DYRK1A were co-transfected into NCI-H1299 cells and the amount of phospho-tau protein (p-tau) was analyzed by Western blot (Figure 2 and supporting information Figure S2 ). Cells transfected with empty vectors were utilized as controls. NCI-H1299 cells were transfected with expression vector encoding FLAG-tagged tau in combination with either empty expression vector or EGFP-tagged DYRK1A. Twenty hours after transfection the cells were incubated for 2 hours with vehicle (-) or the indicated inhibitor concentration before the cells were harvested. Phosphorylated T212 tau was detected by Westernblotting using the polyclonal anti-phospho T212 tau antibody (44-740G, Invitrogen), total FLAGtau was detected by using a monoclonal M2 anti-FLAG antibody (F1804, Sigma-Aldrich) and EGFP-DYRK1A by a polyclonal anti-GFP antibody (Sc-8334, Santa-Cruz). 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 8 AC12, AC15, AC24 and AC25 showed a significant dose-dependent inhibition of pT212-tau phosphorylation, in contrast to AC20, AC22, AC23 and AC27. However, all these compounds inhibited pT212-tau phosphorylation. The degree of kinase inhibition observed at the protein level reflected the one seen in the in vitro activity assay. In general, compounds with K i of 600 nM or tighter showed clear dose-response effects, while compounds with K i values ranging from 1.7 to 3 µM showed inhibition but with significantly greater noise with respect to doseresponse correlation. An exception to this general observation is AC27. This compound inhibits DYRK1A in the pT212-tau phosphorylation assay, however not as potently as it would have been expected from the in vitro activity assay.
Crystal structures
The inhibitors were set up in co-crystallization trials with DYRK1A. Nine of the novel scaffolds ( Figure 1 ) formed co-crystals. The crystal packing and asymmetric unit is similar to the previously published DYRK1A complexes with PKC412 17 or the benzothiazole fragments 18 , with tetramers constituting the asymmetric unit. In general, the best electron density fit is found for protomer A and the greatest disorder is seen in protomer C. Several chains in the asymmetric unit show disulfide bridge formation between the HCD motif and the activation loop cysteine.
However, in many chains the cysteine residues are reduced and/or in a mixed state, with additional evidence of radiation damage due to low amplitude electron density for cysteine C312 17, 18 . The compounds are bound to all four protomers in the tetramer of the asymmetric unit in DYRK1A (Figure 3) . One exception is compound AC22, which lacks electron density for the entire inhibitor in chain C of the tetramer and the ATP-pocket is empty. However, the electron density is clear for the other three chains. The omit difference density maps after simulated annealing for all the nine inhibitors are shown in the supporting information Figure S3 . The crystallographic data and refinement statistics are summarized in supporting information Table   S2 in the supplementary data. (gatekeeper+1) and L241 (gatekeeper+3). The pyridine nitrogen faces the catalytic lysine K188, but the 4 Å distance to the amine nitrogen is too long for a hydrogen bond. AC22 is anchored to the hinge via two hydrogen bonds, which orients the pyridine nitrogen H-bond acceptor towards the catalytic lysine K188. Compared to AC12 and AC15, the distances to K188 are shorter, including one contact at 3.2 Å, within the range of typical hydrogen bond distances. The crystal structure also shows that K188 shares a salt bridge with E203. Similarly, the aminopyrimidine functionality of AC23 is anchored to the hinge, which points the benzamide substituent towards K188, but without a direct hydrogen bond interaction. However, in chain B there is a water molecule that bridges the gap between the amide and K188. The benzamide moiety has a parallel displaced π-π stacking interaction with the gatekeeper phenylalanine F238.
AC24, AC25 and AC28 make three hydrogen bonds to the hinge via the thiazole and two adjoining amines. In addition, the piperazine rings of these compounds have salt bridge interactions with D247 (the gatekeeper+8 residue). They do not interact with K188. Compared to AC24, the addition of an acrylamide group on AC25 weakens binding, and the crystal structure AC20 has only a single hinge binding hydrogen bond, with L241 (gatekeeper+3), rather than a pair (including the gatekeeper+1 residue E239) that is typical for the other inhibitors. AC20
shares a hydrogen bond with the catalytic lysine K188 with its urea oxygen, and also shares a salt bridge with the DFG aspartate D307 via the morpholine nitrogen. It forms in addition a perpendicular π stacking interaction with the gatekeeper phenylalanine. Like all the other inhibitors, AC20 binds in a typical type I binding mode.
The strongest of the inhibitors in this study, AC27 uniquely has no hydrogen bond to the hinge.
It has anchoring hydrogen bonds with K188 and E203 via its diazole group, with N244 via its carbonyl group, and also with the N292 side chain as a C-H--O hydrogen bond with a hydrogen 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 14 binds CLK2 more tightly than DYRK1A. This compound bound also the tyrosine kinases ABL and PDGFR, which is unsurprising, considering that the series of compounds with this core structure were initially designed for targeting BCR-ABL 20 .
AC22 is the only tested inhibitor that shows a stronger inhibition of GSK3β compared to DYRK1A. Other kinases of the CMGC group significantly inhibited by AC22 include CLK2, HIPK1/2 and CDK7. AC22 also interferes with other kinases across several families, albeit with weaker binding affinity.
AC23 exhibited rather weak and unspecific DYRK binding. The main targets of this compound belonged to the CMGC and CAMK families, with DRAK1/2 and ERK5 as the top hits.
The three thiazole compounds, AC24, AC25 and AC28, have slightly varying affinities. While AC24 had greater affinity for DYRKs compared to CLKs, the addition of the acrylamide in AC25 and AC28 shifted the profile towards CLK2, and also decreases the overall selectivity. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58 
AC27, an analog of mTOR inhibitor
NFAT Luc reporter assays
The newly identified compounds were studied in the HEK293 cell line by introducing the NFAT luciferase activity assay (Figure 6 ). The compounds were titrated in increasing amounts from 0.25 µM to 20 µM. AC27, as the most active compound, was titrated from 0.05 µM to 10 µM. With the exception of AC25, all compounds showed activity in the tested cell line. AC12 was found to be active at concentrations up to 5 µM; higher concentrations of this compound led to a drop in the activity, suggesting that AC12 might be toxic at concentrations >5 µM. AC15, despite sharing the same core structure of AC12, showed dose-dependent inhibition up to 20 µM; this compound required a minimum of 5 µM to show considerable activity above the background level. This was also the case for AC20, AC22 and AC24. Based on the NFAT luciferase activity assay, the most active compounds were AC23 and AC27. Specifically, AC27 showed clear activity at 50 nM and thus is approximately 10-fold more active than AC23 and approximately 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 100-fold more active than to the other six inhibitors in this assay. The drop in the activity of AC27 at 10 µM and AC23 at 20 µM may suggest that these concentrations might be toxic. As mentioned above, AC25 was the only inactive compound with respect to this assay, showing an apparent dose-dependent drop in the basal activity, possibly coupled with toxicity for HEK293 cells. Numbers indicate the fold of increase in luciferase activity upon inhibition of DYRK1A (A). The most active compound AC27 shows a 1.5fold increase in luciferase activity at 50 nM. For comparison harmine is included in the same assay (B). Even though harmine reached a higher activity and does not display the drop in activity as AC27 at higher concentrations toward DYRK1A, AC27 is active at much lower concentrations. 100 nM AC27 leads to the same activity as 5 µM harmine, making AC27 nearly 50 times more active than harmine in this particular cellular assay. properties of helix C. Although AC12, AC15 and AC22 have similar molecular weights and similar binding poses with the hinge region, their binding strengths differ greatly. AC12 and AC15 were the strongest binders, while AC22 was one of the weakest that still enabled cocrystal structure determination. (The relatively weak binding of AC22 is also reflected in the fact that one of the ATP pockets of the four DYRK1A chains in the asymmetric unit of the crystal structure was empty). Detailed comparison of the structures AC12, AC15 and AC22 shows that the pyridine rings occupy the same volume, and the overlap of the nitrogen atoms anchored to the hinge is apparent ( Figure 7A) . However, the methoxy group of AC22 on the aniline ring most likely weakens the binding. The structure shows that the methoxy group pushes the compound away from the hinge, hence increasing intramolecular strain. The remaining inhibitors for which a cocrystal structure could be obtained are selective towards the CMGC kinase group and DYRKs. However, all show additional cross reactivity against targets outside the CMGC group.
Inhibitor AC20 inhibits DYRK1A, however the strongest inhibition of CMGC group kinases is of CLK2, and similar or stronger inhibition is seen of TK group members ABL and PDGFRB (with considerable variation across ABL mutants). AC20 is clearly hydrogen bonded to K188, Figure 7B ). As described above, the crystal structure of AC25 showed that the additional acrylamide was associated with a shift of its parent phenyl ring away from its position in AC24, presumably to avoid a steric clash with D307 (of DFG), but possibly colliding with V173. Two characteristics distinguish AC28 from AC24 and AC25: the acrylamide functional group at the meta position, and the lack of a 2-methoxy substituent in aniline. These properties changed the inhibition 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 20 selectivity pattern significantly, eliminating their inhibitory activity against many CAMK family kinases, JNK kinases, and adding the binding to the pseudokinase domains of JAK1 and TYK2.
Moreover, the cross reactivity towards MAST1 in the AGC group of AC24 and AC25 was lost in AC28. These clear and specific dependencies warrant further more detailed structural studies.
AC23 and AC27 have a potential bridging water molecule in the binding pocket that could be an important affinity determinant. In fact, for AC27 the water in the binding pocket is the only apparent interaction that anchors AC27 to the hinge. The waters are unambiguous only in chain B (AC23) or chain D (AC27) in the electron density of the DYRK1A tetramer. Despite the missing electron density, a water bridging interaction may however be important, because multiple bridged geometries may exist. Optimization of these compounds can take this into account (Figure 3 and 8) . The structure of the inhibitor in the ATP pocket of DYRK1A includes a water molecule that enables bridging interactions between the inhibitor and the K188, E203 and D307 for AC23, and between the inhibitor and the hinge carbonyl of E239 and amide nitrogen of L241 for AC27.
There is no clear electron density for a water in the other chains; however, some diffuse electron density suggests it to be present there also. 
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AC23 and especially AC27 were the most active compounds in the cell line assay (NFATluc, Figure 6 ). These compounds were active at lower concentrations compared to harmine. AC23 reached a twofold activity increase at 1 µM, and AC27 reached twofold activation already at 0.1 µM. In contrast, harmine reaches this level only at ~5 µM, i.e. AC23 and AC27 may be seen as 5x and 50x as active, respectively. On the other hand, both AC23 and AC27 show reduced activity at concentrations above 10 µM. This could be an indication that these higher concentrations introduce toxicity to the cells, while harmine continues to exhibit dose dependent inhibition at these concentrations.
As mentioned above, several DYRK1A inhibitors were identified in the recent past, but none of these compounds has met the selectivity standards needed for use as probe molecules. Harmine, one of the most commonly used inhibitors in DYRK1A related research, has strong cross inhibition of monoamine oxidase that would create severe side effects. The low selectivity also makes harmine unsuitable as a probe to test DYRK1A inhibition in cell lines. Efforts to eliminate the MAO inhibition while keeping the DYRK1A inhibition lead to the harmine derivative AnnH75 25 . Another DYRK1A inhibitor, green tea flavonol epigallocatechin-gallate (EGCG), was shown to correct cognitive deficits in Down syndrome mouse models and in humans 26 . However, it also potentially has multiple targets (and correspondingly is under consideration for use a broad range of disorders) and cannot be considered a DYRK specific inhibitor. The compounds EHT1610 and EHT5372 are among the most selective DYRK inhibitors identified so far 27, 28 .
Crystal structures of these compounds in complex with a kinase are available for DYRK2 (5LXD and 5LXC). A comparison of this scaffold to AC27, one of the more selective compound in our series, shows some remarkable similarities. First, a structural comparison of the EHT1610 and EHT5372 compound bound to DYRK2 suggests that the canonical hinge binding may be less essential for high affinity binding in DYRK 28 as it is for AC27, because its hinge interaction is only indirect, via a bridging water molecule. Secondly, all three compounds interact with the Ploop, and the trifluoromethyl in AC27 or the 2-fluoro-and 2-chloro-benzyl group of EHT1610 and EHT5372 occupy the same space. One major difference is in the overall orientation of the inhibitors. Considering them "U" or horse-shoe shaped, the opening of the "U" for AC27 points toward the P-loop aryl F160, while the orientation is reversed for the EHT inhibitors. Additional inhibitors of DYRK1A discussed in the literature include a derivative of a marine sponge alkaloid Leucettine L41, which has shown some efficacy in mice to prevent memory impairment 29 . Benzothiazole fragments 18, 30 and the independently developed benzothiazoles INDY 23 and BINDY 24 are also effective inhibitors of DYRK1A. FINDY is a selective inhibitor of the kinase DYRK1A that targets its folding process 31 . A detailed review article of the most 
CONCLUSIONS
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4-[3-(Pyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-5-yl]benzene-1-sulfonamide (XMD7-117, AC-12
1-(4-
tert-Butyl
Expression and purification
A DYRK1A construct comprising the kinase domain (126-490) was cloned into pEXP17 with N-terminal 6x(HIS) affinity tags and TEV protease cleavage sites 17, 18 . Expression was done in shaker flask cultures overnight at 17.8 °C in TB media. For the purification of DYRK1A the cells were resuspended in a lysis buffer containing 50 mM sodium phosphate buffer pH 8.0 with 500 mM NaCl and of 0.5% Tween20. Purification was done via NiNTA columns and an imidazole gradient (10-500 mM), followed by a TEV cleavage overnight and a second NiNTA to separate the kinase from uncut protein and the protease. Final purification for DYRK1A was done via size exclusion chromatography (SEC buffer: 50 mM MOPS pH 6.8, 50 mM KCl, 2 mM β-Me). Table S2 .
Activity assay
The determination of the IC 50 constants for DYRK1A was done by an ATP regenerative NADH consuming assay 16 . The enzyme velocity was measured at 340 nm over a time period of 300 s at room temperature. ATP and the peptide RRRFRPASPLRGPPK (DYRKtide) were used as substrates. The reaction mixture was composed of 75 µl of 100 mM MOPS buffer pH 6.8, 10
mM KCl, 10 mM MgCl, 1 mM phosphoenolpyruvate, 1 mM DYRKtide, 1 mM β-ME, 15 units/mL lactate dehydrogenase, 10 units/ml pyruvate kinase and 10.7 mM NADH. 10 µl of 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 directly using anti-GFP Dylight 800-conjugated antibody or IRDye 800CW-conjugated goat antirabbit IgG (H&L) (1:10000) or IRDye 680LT-conjugated donkey anti-mouse IgG (H&L)
(1:10000) and the Odyssey Infrared Imaging System (Li-Cor Biosciences). Protein molecular mass was estimated using the MagicMark Western protein standard (Life technologies).
Antibodies
The polyclonal antibody against tau phosphorylated at threonine 212 (44-740G) was purchased from (Life Technologies). The monoclonal antibody against FLAG (F1804) was purchased from Sigma-Aldrich. The anti-GFP Dylight 800-conjugated antibody (600-145-215) was purchased from Rockland. The IRDye 800CW-conjugated goat anti-rabbit IgG (H&L) and IRDye 680LT-conjugated donkey anti-mouse IgG (H&L) were purchased from Li-Cor Bioscience. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 35
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